173 related articles for article (PubMed ID: 24982384)
1. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience.
Benson C; Vitfell-Rasmussen J; Maruzzo M; Fisher C; Tunariu N; Mitchell S; Al-Muderis O; Thway K; Larkin J; Judson I
Anticancer Res; 2014 Jul; 34(7):3663-8. PubMed ID: 24982384
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
3. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
[TBL] [Abstract][Full Text] [Related]
4.
Wagner AJ; Ravi V; Riedel RF; Ganjoo K; Van Tine BA; Chugh R; Cranmer L; Gordon EM; Hornick JL; Du H; Grigorian B; Schmid AN; Hou S; Harris K; Kwiatkowski DJ; Desai NP; Dickson MA
J Clin Oncol; 2021 Nov; 39(33):3660-3670. PubMed ID: 34637337
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
Starbuck KD; Drake RD; Budd GT; Rose PG
Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa).
Bergamo F; Maruzzo M; Basso U; Montesco MC; Zagonel V; Gringeri E; Cillo U
World J Surg Oncol; 2014 Feb; 12():46. PubMed ID: 24575738
[TBL] [Abstract][Full Text] [Related]
7. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
[TBL] [Abstract][Full Text] [Related]
8. Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review.
Raimondi A; Colombo F; Pintarelli G; Morosi C; Renne SL; Frezza AM; Saponara M; Dei Tos AP; Mazzocchi A; Provenzano S; Casali PG; Stacchiotti S
Anticancer Drugs; 2018 Jul; 29(6):589-595. PubMed ID: 29668485
[TBL] [Abstract][Full Text] [Related]
9. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
[TBL] [Abstract][Full Text] [Related]
10. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
Italiano A; Delcambre C; Hostein I; Cazeau AL; Marty M; Avril A; Coindre JM; Bui B
Ann Oncol; 2010 May; 21(5):1135-7. PubMed ID: 20215136
[No Abstract] [Full Text] [Related]
11. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors: two case reports.
Batereau C; Knösel T; Angele M; Dürr HR; D'Anastasi M; Kampmann E; Ismann B; Bücklein V; Lindner LH
Anticancer Drugs; 2016 Mar; 27(3):254-8. PubMed ID: 26645891
[TBL] [Abstract][Full Text] [Related]
12. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
[TBL] [Abstract][Full Text] [Related]
13. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Emons G; Kurzeder C; Schmalfeldt B; Neuser P; de Gregorio N; Pfisterer J; Park-Simon TW; Mahner S; Schröder W; Lück HJ; Heubner ML; Hanker L; Thiel F; Hilpert F
Gynecol Oncol; 2016 Mar; 140(3):450-6. PubMed ID: 26731724
[TBL] [Abstract][Full Text] [Related]
14. Phase II Trial of
Wagner AJ; Ravi V; Riedel RF; Ganjoo K; Van Tine BA; Chugh R; Cranmer L; Gordon EM; Hornick JL; Du H; Ding L; Schmid AN; Navarro WH; Kwiatkowski DJ; Dickson MA
J Clin Oncol; 2024 May; 42(13):1472-1476. PubMed ID: 38427923
[No Abstract] [Full Text] [Related]
15. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
[TBL] [Abstract][Full Text] [Related]
16. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
Afshar M; Pascoe J; Whitmarsh S; James N; Porfiri E
Drug Des Devel Ther; 2015; 9():13-9. PubMed ID: 25552898
[TBL] [Abstract][Full Text] [Related]
17. PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide.
Scheppach W; Reissmann N; Sprinz T; Schippers E; Schoettker B; Mueller JG
World J Gastroenterol; 2013 Mar; 19(10):1657-60. PubMed ID: 23539498
[TBL] [Abstract][Full Text] [Related]
18. A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
Fujisaka Y; Yamada Y; Yamamoto N; Horiike A; Tamura T
Jpn J Clin Oncol; 2010 Aug; 40(8):732-8. PubMed ID: 20430774
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.
Oza AM; Elit L; Tsao MS; Kamel-Reid S; Biagi J; Provencher DM; Gotlieb WH; Hoskins PJ; Ghatage P; Tonkin KS; Mackay HJ; Mazurka J; Sederias J; Ivy P; Dancey JE; Eisenhauer EA
J Clin Oncol; 2011 Aug; 29(24):3278-85. PubMed ID: 21788564
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.
Lamm W; Vogl UM; Bojic M; Zielinski C; Klingler C; Kramer G; Schmidinger M
Acta Oncol; 2012 Jan; 51(1):101-6. PubMed ID: 21736504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
